M.F.
CโโHโโDโNโOโ
Storage Condition
Store at refrigerator (2-8ยฐC) for long term storage
Synonyms
rac-Ambrisentan-d3, 1189479-60-4
Application Notes
Useful research chemical for a range of applications
Hazard Compound
No -Refer MSDS for accurate information
rac-Ambrisentan-d3 is a drug product that is used as an analytical standard for HPLC, as well as in research and development of drugs.
Refund Policy
We are committed to offering products of the highest quality in order to meet the needs of our customers, and have elaborate systems in
place to ensure that material specifications, their certification and all handling and storage conditions are communicated at the time of
material handover.
We have invested in the highest quality packaging materials and use international logistics partners to service our customers. While all
possible precautions have been taken to deliver the required product(s), there may be some rare situations when our product does not
meet your requirements. Should that arise, please contact us with your concerns and we will endeavour to address them on a priority
basis. If there is no other option, we will either replace your product(s) or issue a refund or account credit, whichever you prefer.
If there is an issue with one or more of our products, our policy is that it must be reported to us within 45 days of your receiving shipment.
While we will always address product issues after the 45 day return window has passed, we cannot issue a refund or account credit. As
always, we appreciate your support.
rac-Ambrisentan-d3 usage and description
Rac-Ambrisentan D3 is a medication used to treat pulmonary arterial hypertension (PAH). It is a derivative of the endothelin receptor antagonist, ambrisentan. It works by blocking the effects of endothelin, a hormone that constricts blood vessels and contributes to the development of PAH.
The chemical structure of Rac-Ambrisentan D3 consists of a pyridine ring, a pyrrolidine ring, and a carboxylic acid group. It is available in the form of a tablet for oral administration.
The recommended starting dose of Rac-Ambrisentan D3 is 5 mg once daily, with or without food. The dose may be increased after four weeks to 10 mg once daily based on the patient's response and tolerability.
Rac-Ambrisentan D3 should not be used in patients with severe liver impairment or in those who are pregnant or breastfeeding. It may also interact with other medications, including cyclosporine and rifampin.
Common side effects of Rac-Ambrisentan D3 include headache, flushing, nasal congestion, and peripheral edema. In rare cases, it may cause liver damage or pulmonary edema.
In conclusion, Rac-Ambrisentan D3 is a medication used to treat PAH by blocking the effects of endothelin. It is available in the form of a tablet for oral administration and should only be used under the supervision of a healthcare professional.